VendorInvestigate result on a Qingdao retatrutide lot lands 3.6 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
April 2024 — Vol. 1, No. 4
Page 2 of 4 of this archive, newest first.
Also filed — page 2
the rolling newsroom, April 2024What changed at KP in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Shenzhen: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Denmark health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
A supplier suspends shipping to France after 21 consecutive customs detentions
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a GL Biochem exenatide lot at 98.1%, against 96.5% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Qingdao: 17 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
QYB declines, for the 10th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Ireland health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What an 11% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
The online reseller trading as Adamant Research Supply closes after 7 years
A proper account of an operation that existed, and of what closing it cost.
Nigeria declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Spain caps tirzepatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What changed at WWB in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Australia health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 21 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.